LEIDEN, NETHERLANDS, Biopharmaceutical company focusing on RNA-modulating therapeutics, announced that it has raised a round of financing led by new investor New Enterprise Associates (NEA) and was supported by existing Prosensa investors, Abingworth, Life Sciences Partners, Gimv, Idinvest Partners and MedSciences Capital.
Read More